Clinical Trial Update: A Study of TAS-120 in Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TAS-120 (futibatinib) in metastatic breast cancer with FGFR1 high amplification or FGFR2 amplification was terminated, and results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TAS-120 (futibatinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Metastatic Breast Cancer, FGFR 1 High Amplification | Phase 2 | Status: TERMINATED | Results posted: 2025-11-13